WPWenying Peng

Wenying Peng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenying Peng has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Bolin Chen

    The Second Department of Thoracic Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

    1 shared publication
  • Chunbo Chen

    Department of Critical Care Medicine, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), China

    1 shared publication
  • Fang Xu

    The Second Department of Thoracic Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

    1 shared publication
  • Han Wang

    University of Electronic Science and Technology of China Sichuan Provincial People’s Hospital, Sichuan Province, China

    1 shared publication
  • Jia Li

    The Second Department of Thoracic Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

    1 shared publication
  • Jiaxin Li

    State Key Laboratory of Natural Medicines

    1 shared publication

Latest Publications

  • Open Access

    Risk Factors and Prediction of Postoperative Delirium in Aortic Arch Replacement: A Retrospective Cohort Study

    by Miaoxian Fang, Jiaxin Li, Rong Zeng, Yuming Huang, Yingkai Xiao, Wenying Peng, Siyi Liu, Han Wang, Weiping Xiong, Chunbo Chen, et al.

    Objective: This study aimed to explore the risk factors and prediction of postoperative delirium (POD) in aortic arch replacement. Methods: The preoperative, intraoperative, and postoperative clinical data of patients undergoing aortic arch replacement in our hospital from January 1, 2018, to March 31, 2019, were retrospectively analyzed. According to whether POD occurred, cases were divided into delirium group and control group. The clinical data of the patients were firstly screened by univariate analysis, and then the meaningful variables were analyzed by multivariate logistic regression analysis. The receiver operating characteristic curve was used to analyze the meaningful factors in predicting the occurrence of POD after aortic arch replacement. Results: A total of 162 patients were included in the study. The prevalence of POD was 46.9% (n = 76). The results of univariate and multivariate analyses showed that the intraoperative minimum mean arterial pressure (MAP) (odds ratio [OR] = 0.635, 95% confidence interval [CI] = 0.5510.731, P < 0.001), postoperative C-reactive protein (OR = 1.010, 95% CI = 1.0031.018, P = 0.005), and postoperative infection (OR = 3.148, 95% CI = 1.1188.867, P = 0.030) were the independent risk factors for POD in aortic arch replacement. Among them, the intraoperative minimum MAP has the best prediction effect. When its cutoff value reaches ≤ 49 mmHg, the specificity for predicting POD is 84.88% and the sensitivity is 81.58%. Conclusions: A lower intraoperative minimum MAP is an independent risk factor and has the predictive value for POD in aortic arch replacement.

  • Open Access

    Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy

    by Meilin Jiang, Wenying Peng, Xingxiang Pu, Bolin Chen, Jia Li, Fang Xu, Liyu Liu, Li Xu, Yan Xu, Jun Cao, et al.

    Background: Selecting patients who potentially benefit from immune checkpoint inhibitors (ICIs) is critical. Programmed death ligand-1 (PD-L1) protein immunohistochemical expression on cancer cells or immune cells and next-generation sequencing-based tumor mutational burden (TMB) are hot spots in studies on ICIs, but there is still confusion in the testing methods. Because blood samples are much easier for clinical application, many potential peripheral biomarkers have been proposed. This study identified blood parameters associated with the outcome of non-small cell lung cancer (NSCLC) patients with ICI monotherapy. Materials and Methods: Data from 76 NSCLC patients were analyzed retrospectively. To assess the connection between survival and peripheral blood markers measured before the first and fifth doses of ICI treatment, we utilized Cox regression model survival analysis and receiver operating characteristic (ROC) curve analysis to assess the markers. Results: In the nivolumab cohort, the optimal cutoffs for predicting 11-month overall survival (OS) were 168.13 and 43 g/L for platelet-to-lymphocyte ratio (PLR) and albumin, respectively. When patients were grouped with PLR and albumin, a significant difference in SD-PR vs. PD rate was found between the high and low groups, which was not found when the patients were grouped by PD-L1 expression. Patients with high PLR (>168.13) or low albumin ( ≤ 43 g/L) before ICI had a significantly increased hazard of progression, separately (for PLR, P = 0.006; for albumin, P = 0.033), and of death (for PLR, P = 0.014; for albumin, P = 0.009) compared with those patients who had low PLR or albumin levels. More importantly, we found that a higher PLR (>168.13) before the fifth dose of ICIs was also a prognostic biomarker, which significantly correlated with shorter OS in both the nivolumab (P = 0.046) and durvalumab cohorts (P = 0.028). Conclusions: PLR and albumin may help in the stratification of high progression and death risk groups in advanced NSCLC patients treated with nivolumab and durvalumab monotherapy.